Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Consolidated Net Income: 2009-2025

Historic Consolidated Net Income for Gyre Therapeutics (GYRE) over the last 16 years, with Sep 2025 value amounting to $5.9 million.

  • Gyre Therapeutics' Consolidated Net Income rose 107.84% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 112.80%. This contributed to the annual value of $16.9 million for FY2024, which is 119.58% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Consolidated Net Income of $5.9 million as of Q3 2025, which was up 276.65% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Consolidated Net Income peaked at $51.6 million during Q2 2022, and registered a low of -$101.8 million during Q4 2023.
  • Moreover, its 3-year median value for Consolidated Net Income was $3.8 million (2023), whereas its average is -$5.3 million.
  • As far as peak fluctuations go, Gyre Therapeutics' Consolidated Net Income plummeted by 453.20% in 2021, and later surged by 359.09% in 2022.
  • Over the past 5 years, Gyre Therapeutics' Consolidated Net Income (Quarterly) stood at -$20.3 million in 2021, then plummeted by 41.75% to -$28.8 million in 2022, then tumbled by 253.66% to -$101.8 million in 2023, then skyrocketed by 99.57% to -$433,000 in 2024, then spiked by 107.84% to $5.9 million in 2025.
  • Its last three reported values are $5.9 million in Q3 2025, $1.6 million for Q2 2025, and $3.7 million during Q1 2025.